Hi, this is Theresa Agnew, CEO of BioGaia. And Alex and I are here to present our Q3 results.
So sales were 327 million SEK, which is an increase of 7% due to higher sales in the Americas as well as the Asia Pacific. Growth overall was 14% when excluding currency effects. Year to date, our growth is 8% excluding currency effects and 4% including currency. Our sales in the Asia Pacific for the quarter increased by 17%, in the Americas increased by 10%, and in EMEA decreased by 4%, primarily due to sales in Eastern Europe. We saw strong growth following increased media investments in the US and among other priorities. We prioritized direct markets such as Canada, the UK, and Australia.
With our increased media, we've been attracting new consumers to the brand and enhancing our brand awareness for the quarter. Our EBIT is 86 million SEK and our EBIT margin is 26%. And as you can see, this compares to a 14% EBIT margin last year.
This was lower due to the impairment loss of 51 million.
Our year-to-date EBIT margin is now 27%.
Just to remind you of our BioGaia company strategy, we have three strategic pillars.
The first is Grow the Core, in which we focus on gut health, colic, oral health, as well as immune health. Our second focus is expansion through direct markets.
And our third is breakthrough innovation.
This is where market creation opportunities arise for using probiotics in new areas.
The foundations of our company are, of course, our people and culture.
Investing for profitable growth, digital as an enabler of our business as well as our go-to-market driven by science, which has been a foundation for over 30 years for the company, and sustainable solutions with a strong focus on sustainability, we are delivering on our strategy in terms of our Grow the Core.
We're driving growth in our pediatric and adult health segments. We're investing in marketing and sales activities to drive strong growth in our direct markets. As I mentioned, in the US, we're successfully launching new products in our core health areas. Last year we launched BioGaia Gastrus Pure Action, and this quarter we're rolling it out to more markets.
This quarter, we also launched Prodentis Fresh Breath, which is a new product that combines our probiotics with zinc. It works on gums and teeth, as well as providing fresh breath.
We're rolling out many of our other products in partner markets and direct markets as well.
In terms of our second strategy, expansion through direct markets, we launched France as a direct market in Q2.
And that market is starting to do well. In Q3, we're preparing to launch Germany and Austria in early 2026. And actually, in Q3, France had its strongest month with record sales in September.
So, we have high ambitions in France to continue our growth into next year. Australia, which we launched in 2024.
Now, with all of our marketing and selling efforts, BioGaia Protectis Easydropper is number one in the market. We also have record sales in the US market due to the investments that we've been putting into that market. Our direct markets are growing ahead of our partner markets in terms of our third strategic area, breakthrough innovation. As you may have seen in a press release, we've established a new subsidiary called BioGaia New Sciences AB that will focus on skin health, which is a new breakthrough innovation area for us. We are rolling out our BioGaia Probiotic Ointment to more markets. So now you will see we have new launches of our probiotic ointment.
So speaking of launches, this shows you all the product launches we have had as we expand our new products into more markets for the quarter. We have rolled out our probiotic ointment in Sweden, Finland, and the UK. We launched Prodentis Fresh Breath lozenges. As I mentioned in the US, in Argentina we rolled out a number of our products, Slovakia and in the US. We launched our BioGaia Gastrus Pure Action capsules, which we first introduced in Finland last year. And then, we also rolled out Gastrus Pure Action capsules in Australia and New Zealand.
All of these launches are doing very well, especially Gastrus Pure Action. It is driving increased sales in our adult gut health area. As well. It's continuing to do extremely well in Finland after a year of launch without cannibalizing our chewable Gastro product.
Some of the key events that happened during the quarter, as I said, we launched our BioGaia New Sciences AB subsidiary at an extraordinary general meeting in August.
We resolved to elect Mauricio Graber as our new chairman of the board. Also, Mauricio entered into an agreement to purchase some class B shares from the anchor shareholder Anatom Holding. BioGaia also announced a distribution agreement in Germany and Austria, which we will be starting in early 2026. We also announced the launch of a new product, Prodentis Fresh Breath. And as I said, it launched first in the US in the quarter. And more recently, we announced the publication of a study on our new patented strain, L.
reuteri BG-R46. This has actually been published in a journal called Beneficial Microbes.
We also introduced a press release on this, highlighting how, as expected, this new patented strain is safe and well characterized. In terms of sales per segment. In our Pediatrics area, sales grew by 7% this quarter. And if you exclude currency effects, it's 14%.
This is mainly due to increased sales protecting against the US drop in Asia Pacific. Latin America specifically. Some markets that did very well were Indonesia, Vietnam, and Mexico.
In terms of adult health, our sales increased by 6% in the quarter, rising to 13% when excluding currency effects. We saw particularly strong growth for BioGaia in the US. And as you can see, our Pediatric segment remains at about 75% of our sales. In terms of the regions, as I said earlier, EMEA sales decreased by 4%.
This was mainly due to Eastern Europe and Italy.
But one comment on Italy: Italy is growing well for us this year, so the decline that we saw was mainly due to order variability because we saw higher orders in Q2 in France. As I said, we achieved record sales in September.
We are driving increased distribution. We're driving recommendations through pharmacies.
So we anticipate that this growth will continue.
And in Turkey, we have signed a long-term distribution agreement with one of our partners, Abbott.
Abbott is actually a long-standing BioGaia partner.
We partner with them in the Middle East, Latin America, and some other Asia Pacific markets. So we have now signed an agreement with Abbott Turkey for the market of Turkey.
In Asia Pacific, our sales increased by 17%. This was mainly seen in Vietnam, as well as Indonesia and specifically in Australia.
In one of our direct markets, we are expanding distribution, increasing our marketing activities, and growing our market share in the Americas.
Our sales increased by 10%.
This was mainly due to the growth in the US and Mexico, particularly in the US. We're achieving record-breaking sales.
In the quarter.
We successfully launched two new products, as I mentioned, which are BioGaia Gastrus Pure Action capsules and BioGaia Prodentis Fresh Breath. Both products are off to a fast start in the US.
So I will now turn it over to Alex to go through our financials in more detail.